Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target at $30.56

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has earned a consensus rating of "Moderate Buy" from the fourteen research firms that are covering the stock, MarketBeat.com reports. Seven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $30.56.

Several brokerages have issued reports on KROS. Truist Financial dropped their price objective on Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating on the stock in a report on Wednesday, April 9th. Scotiabank dropped their price objective on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a report on Monday, May 12th. Bank of America lowered Keros Therapeutics from a "buy" rating to a "neutral" rating and dropped their price objective for the stock from $32.00 to $18.00 in a report on Tuesday. Wedbush reiterated a "neutral" rating and set a $15.00 target price on shares of Keros Therapeutics in a research note on Friday, May 30th. Finally, Wells Fargo & Company decreased their target price on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, February 27th.

Insider Activity at Keros Therapeutics

In other news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of Keros Therapeutics stock in a transaction that occurred on Wednesday, April 9th. The stock was purchased at an average price of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the transaction, the insider now directly owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. This trade represents a 27.01% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 20.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Keros Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. FNY Investment Advisers LLC acquired a new stake in shares of Keros Therapeutics during the 1st quarter valued at approximately $25,000. CWM LLC lifted its position in shares of Keros Therapeutics by 10,157.7% during the 1st quarter. CWM LLC now owns 2,667 shares of the company's stock valued at $27,000 after acquiring an additional 2,641 shares during the period. AlphaQuest LLC lifted its position in shares of Keros Therapeutics by 469.0% during the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock valued at $57,000 after acquiring an additional 2,964 shares during the period. Virtus ETF Advisers LLC lifted its position in shares of Keros Therapeutics by 107.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company's stock valued at $61,000 after acquiring an additional 1,998 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Keros Therapeutics during the 4th quarter valued at approximately $90,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Stock Performance

Shares of KROS stock traded down $0.08 during mid-day trading on Wednesday, hitting $13.56. 377,905 shares of the stock were exchanged, compared to its average volume of 865,579. The stock's fifty day simple moving average is $13.81 and its two-hundred day simple moving average is $16.81. The stock has a market capitalization of $550.74 million, a price-to-earnings ratio of -2.60 and a beta of 1.31. Keros Therapeutics has a 12-month low of $9.12 and a 12-month high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $3.62 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $3.63. The company had revenue of $211.25 million for the quarter, compared to analyst estimates of $84.62 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. During the same quarter last year, the company posted ($1.21) earnings per share. On average, research analysts expect that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.